Cytotoxicity of the small molecule Bcl-2 antagonist, HA14-1, and selected anticancer drugs in follicular lymphoma B-cells.

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Wlodkowic, Donald en
dc.contributor.author Skommer, JS en
dc.contributor.author Matto, M en
dc.contributor.author Eray, ME en
dc.contributor.author Pelkonen, J en
dc.coverage.spatial Paris, France en
dc.date.accessioned 2011-12-02T01:06:17Z en
dc.date.issued 2005 en
dc.identifier.citation 20th European Congress of Pathology, Paris, France. P107. 2005 en
dc.identifier.uri http://hdl.handle.net/2292/9741 en
dc.description.abstract The Bcl-2 overexpression is a hallmark of follicular lymphoma (FL). Since patients with FL often suffer from progressively resistant to chemotherapy refractory disease, the development of new regiments is required. In this study we analyzed for the first time the effects of a Bcl-2 antagonist, HA14-1, alone and in combination with antineoplastic agents commonly used against follicular lymphoma, in human FL cell lines with t(14;18). The cell lines were established from patient samples send for PAD analysis and earlier analysed in detail. All cells were sensitive to HA14-1 induced cytotoxicity (the LC50s of 4.5 to 12.6μM) and apoptosis. Moreover, HA14-1 enhanced dexamethasone and doxorubicin mediated (in schedule independent and dependent manner, respectively) cytotoxicity and apoptosis, but antagonized with vincristine, in all FL cells. Together these findings warrant further in vivo studies and provide conceptual basis for therapeutic intervention in follicular lymphoma. en
dc.relation.ispartof 20th European Congress of Pathology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Cytotoxicity of the small molecule Bcl-2 antagonist, HA14-1, and selected anticancer drugs in follicular lymphoma B-cells. en
dc.type Presentation en
pubs.begin-page P107 en
dc.rights.holder Copyright: the author en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Conference Oral Presentation en
pubs.elements-id 249971 en
pubs.record-created-at-source-date 2011-12-02 en


Full text options

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse